Overview
On National Science Day, Union Minister of State (Independent Charge) for Science & Technology, Dr. Jitendra Singh inaugurated two landmark initiatives at the BRIC‑RGCB: the Central Facility for Recombinant Cells and Sensors and a dedicated GMP unit for pre‑commercial biologics and cell‑based therapies.
Key Developments
- Inauguration of the Central Facility for Recombinant Cells and Sensors with an investment of ≈ Rs 60 crore by the DBT.
- Announcement of a new GMP facility worth Rs 80 crore, to support production of CAR‑T therapy and other biologics on a “pay‑and‑use” basis.
- Release of the book “Quantum Physics: One Hundred Magical Years” by Prof. V.P.N. Nampoori, underscoring the Ministry’s emphasis on fundamental research.
Important Facts
The biotech ecosystem in India has expanded dramatically: the number of biotech start‑ups rose from ≈ 50–70 in 2014 to **over 11,000** today. The bioeconomy has grown sixteen‑fold, from **US$10 billion** to **US$166 billion**, with a target of **US$300 billion** in the near future. These gains are anchored in the recently launched BioE3 Policy, which is one of the few global policies focusing on economy, environment and employment through biotechnology.
The new facility houses a large panel of engineered recombinant cells and advanced screening platforms, enabling rapid target‑specific drug discovery for diseases such as diabetes, fatty liver disease, and various cancers (colon, oral, breast, cervical). The Minister highlighted India’s rising non‑communicable disease burden and the need for integrated preventive (e.g., HPV vaccination) and therapeutic strategies.
Exam Relevance
Understanding the intersection of science policy and economic development is crucial for GS III (Science & Technology). The initiatives illustrate how government‑funded infrastructure can translate research into commercial products, a key theme in questions on biotechnology, public health, and industrial policy. The scale of investment and the focus on GMP compliance also tie into discussions on regulatory frameworks and quality assurance in the pharmaceutical sector.
Way Forward
For sustained growth, the Ministry should:
- Facilitate greater industry‑academia collaboration through “pay‑and‑use” models for the new facilities.
- Expand funding for deep‑tech start‑ups, especially those working on cell‑based therapies and marine biotechnology, aligning with coastal state strengths.
- Strengthen regulatory capacity to ensure that products emerging from the GMP unit meet international standards, enhancing export potential.
- Promote skill development programmes to create a skilled workforce capable of operating advanced recombinant‑cell platforms.
These steps will reinforce India’s ambition to become a global hub for biomanufacturing and solidify the bio‑driven growth trajectory envisioned under the BioE3 Policy.